Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALLR Stock Summary
Top 10 Correlated ETFs
ALLR
In the News
Allarity Therapeutics to Present at Biomarkers 2024
Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.
Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?
Allarity Therapeutics (NASDAQ: ALLR ) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib. That clinical trial saw the company testing the effectiveness of stenoparib in women with advanced ovarian cancer.
Allarity Therapeutics to Present at Biomarkers Europe 2023
BOSTON , October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023. The presentation will focus on Allarity's development of drug-specific DRP® companion diagnostics (CDx) for oncology therapeutics, featuring clinical validation for several exemplary DRP® CDx.
Top 5 Health Care Stocks That Could Blast Off In August - Biolase (NASDAQ:BIOL), Allarity Therapeutics (NASDAQ:ALLR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?
Shares of clinical-stage precision medicine company Allarity Therapeutics (NASDAQ: ALLR ) initially soared to a 60% gain for the midweek session before paring down gains to roughly 30%. Undergirding sentiment was early-stage data evaluating the efficacy of Ixempra — a metastatic breast cancer therapeutic — at multiple sites in Europe.
Why Is Allarity Therapeutics (ALLR) Stock Down 22% Today?
Allarity Therapeutics (NASDAQ: ALLR ) stock is falling hard on Wednesday after the clinical-stage pharmaceutical company launched a public offering. That public offering has the company selling up to $20 million in shares, as well as warrants to purchase its stock.
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
Allarity's stock falls after saying enrollment in two clinical trials is slow
Shares of Allarity Therapeutics Inc. ALLR, -4.51% plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to enroll enough patients in Phase 2 studies for Ixempra and senoparib, citing the impact of the pandemic on staffing for clinical-trial sites. The company is testing Ixempra as a treatment for metastatic breast cancer and stenoparib for ovarian cancer.
Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect
Allarity Therapeutics announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post-split share for every 35 pre-split shares. The post Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect appeared first on Pulse 2.0.
Why Is Allarity Therapeutics (ALLR) Stock Down 23% Today?
Allarity Therapeutics (NASDAQ: ALLR ) stock is sliding lower on Friday after announcing a reverse stock split. According to a press release, the company plans to enact a one-for-35 reverse stock split.
ALLR Financial details
ALLR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.06 | 0 | 0 | 0 | 0 | |
Net income per share | -127.06 | -44.76 | -167.62 | -2.06 | -5.98 | |
Operating cash flow per share | -89.23 | -63.98 | -94.67 | -2.16 | -6.4 | |
Free cash flow per share | -89.3 | -64 | -94.67 | -2.16 | -6.4 | |
Cash per share | 13.45 | 2.63 | 125.21 | 0.26 | 0.08 | |
Book value per share | 159.59 | 236.92 | 118.16 | 0.24 | -1.38 | |
Tangible book value per share | -59.88 | -32.12 | -58.82 | -0.98 | -6.34 | |
Share holders equity per share | 159.59 | 236.92 | 118.16 | 0.24 | -1.38 | |
Interest debt per share | 37.72 | 17.77 | 9.97 | 0.51 | 0.9 | |
Market cap | 1.67B | 1.67B | 2.31B | 3.2B | 1.1M | |
Enterprise value | 1.67B | 1.67B | 2.29B | 3.2B | 2.23M | |
P/E ratio | -115.7 | -328.41 | -86.65 | -199.35 | -0.09 | |
Price to sales ratio | 13.88K | 0 | 0 | 0 | 0 | |
POCF ratio | -164.74 | -229.76 | -153.43 | -190.35 | -0.09 | |
PFCF ratio | -164.61 | -229.67 | -153.43 | -190.15 | -0.09 | |
P/B Ratio | 92.11 | 62.05 | 122.93 | 1.69K | -0.4 | |
PTB ratio | 92.11 | 62.05 | 122.93 | 1.69K | -0.4 | |
EV to sales | 13.88K | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -165.57 | -169.08 | -81.02 | -190.62 | -0.12 | |
EV to operating cash flow | -164.69 | -229.97 | -152.2 | -190.45 | -0.18 | |
EV to free cash flow | -164.56 | -229.88 | -152.2 | -190.25 | -0.18 | |
Earnings yield | -0.01 | 0 | -0.01 | -0.01 | -10.85 | |
Free cash flow yield | -0.01 | 0 | -0.01 | -0.01 | -11.62 | |
Debt to equity | 0.05 | 0.07 | 0.06 | 1.98 | -0.47 | |
Debt to assets | 0.03 | 0.05 | 0.02 | 0.26 | 0.11 | |
Net debt to EBITDA | 0.06 | -0.15 | 0.65 | -0.1 | -0.06 | |
Current ratio | 0.71 | 0.31 | 1.02 | 0.44 | 0.14 | |
Interest coverage | -5.32 | -40.65 | -53.22 | -154.54 | -36 | |
Income quality | 0.7 | 1.43 | 0.56 | 1.05 | 1.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 10.02 | |
Payout ratio | 0 | 0 | 0 | 0 | -0.92 | |
Sales general and administrative to revenue | 32.25 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 53.06 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.88 | 0.91 | 0.57 | 0.66 | 0.83 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.07 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.16 | -0.07 | 0 | -0.3 | 0 | |
Stock based compensation to revenue | 2.78 | 0 | 0 | 0 | 0 | |
Graham number | 675.45 | 488.47 | 667.56 | 3.36 | 13.63 | |
ROIC | -0.69 | -0.22 | -1.34 | -5.59 | 11.65 | |
Return on tangible assets | -3.68 | -1.74 | -1.24 | -3.21 | -5.98 | |
Graham Net | -70.04 | -47.74 | -66.73 | -1.28 | -6.9 | |
Working capital | -1.38M | -3.82M | 335K | -6.25M | -12.2M | |
Tangible asset value | -6.79M | -3.64M | -9.35M | -7.66M | -12.62M | |
Net current asset value | -7.36M | -4.84M | -9.8M | -7.69M | -12.64M | |
Invested capital | 0.05 | 0.07 | 0.06 | 1.98 | -0.47 | |
Average receivables | 0 | 1.39M | 1.23M | 1.11M | 908.5K | |
Average payables | 0 | 2.15M | 1.41M | 3.47M | 7.33M | |
Average inventory | 0 | -1000 | -672.5K | -672.5K | 0 | |
Days sales outstanding | 5.04K | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 8.98K | 2.4K | 19.01K | 83.02K | |
Days of inventory on hand | 0 | 0 | -4.63K | 0 | 0 | |
Receivables turnover | 0.07 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.04 | 0.15 | 0.02 | 0 | |
Inventory turnover | 0 | 0 | -0.08 | 0 | 0 | |
ROE | -0.8 | -0.19 | -1.42 | -8.5 | 4.33 | |
Capex per share | -0.07 | -0.03 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -10.4 | -165.73 | -6.39 | -2.24 | -0.87 | |
Operating cash flow per share | -8.96 | -168.89 | -6.7 | -2.17 | -0.84 | |
Free cash flow per share | -9.03 | -168.89 | -6.7 | -2.17 | -0.84 | |
Cash per share | 7.44 | 15.56 | 1.13 | 0.57 | 0.08 | |
Book value per share | 6.93 | -17.89 | -1.94 | -1.37 | -1.38 | |
Tangible book value per share | -28.07 | -530.26 | -28.03 | -5.19 | -6.34 | |
Share holders equity per share | 6.93 | -17.89 | -1.94 | -1.37 | -1.38 | |
Interest debt per share | 14.11 | 205.19 | 4.38 | 0.46 | 0.77 | |
Market cap | 112.31M | 1.27M | 2.46M | 1.85M | 1.1M | |
Enterprise value | 114.02M | 4.78M | 3.53M | 1.62M | 2.23M | |
P/E ratio | -9.89 | -0.1 | -0.26 | -0.08 | -0.16 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -45.92 | -0.4 | -0.98 | -0.34 | -0.66 | |
PFCF ratio | -45.58 | -0.4 | -0.98 | -0.34 | -0.66 | |
P/B Ratio | 59.42 | -3.76 | -3.4 | -0.55 | -0.4 | |
PTB ratio | 59.42 | -3.76 | -3.4 | -0.55 | -0.4 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -35.93 | -1.31 | -0.85 | -0.37 | -0.46 | |
EV to operating cash flow | -46.61 | -1.49 | -1.41 | -0.3 | -1.33 | |
EV to free cash flow | -46.27 | -1.49 | -1.41 | -0.3 | -1.33 | |
Earnings yield | -0.03 | -2.47 | -0.97 | -3 | -1.57 | |
Free cash flow yield | -0.02 | -2.51 | -1.02 | -2.91 | -1.52 | |
Debt to equity | 1.98 | -11.2 | -2.06 | -0.35 | -0.47 | |
Debt to assets | 0.26 | 0.3 | 0.11 | 0.08 | 0.11 | |
Net debt to EBITDA | -0.54 | -0.96 | -0.26 | 0.05 | -0.23 | |
Current ratio | 0.44 | 0.26 | 0.29 | 0.28 | 0.14 | |
Interest coverage | -58.19 | -39.77 | -29.27 | 130.18 | -21.21 | |
Income quality | 0.86 | 0.95 | 1.05 | 1.21 | 0.97 | |
Dividend Yield | 0.01 | 0.13 | 1.84 | 0 | 0 | |
Payout ratio | -0.55 | -0.05 | -1.9 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.66 | 0.76 | 0.72 | 0.68 | 0.83 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -9 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 40.26 | 258.25 | 16.71 | 8.3 | 5.19 | |
ROIC | -1.08 | -0.99 | -5.76 | 2 | 3.53 | |
Return on tangible assets | -0.57 | -1.05 | -0.64 | -1.26 | -0.86 | |
Graham Net | -36.55 | -654.92 | -31.89 | -6.24 | -6.9 | |
Working capital | -6.25M | -8.62M | -8.98M | -11.36M | -12.2M | |
Tangible asset value | -7.66M | -10.05M | -10.44M | -12.84M | -12.62M | |
Net current asset value | -7.69M | -10.08M | -10.46M | -12.87M | -12.64M | |
Invested capital | 1.98 | -11.2 | -2.06 | -0.35 | -0.47 | |
Average receivables | 1.18M | 1.1M | 1.47M | 1.62M | 1.29M | |
Average payables | 5.48M | 6.35M | 7.27M | 7.22M | 7.38M | |
Average inventory | 311K | -666.5K | -14.5K | -164K | -816K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 140.65K | 29.02K | 40.45K | 31.74K | 84.16K | |
Days of inventory on hand | 0 | -6K | 6.52K | -8.16K | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | -0.02 | 0.01 | -0.01 | 0 | |
ROE | -1.5 | 9.27 | 3.29 | 1.64 | 0.63 | |
Capex per share | -0.07 | 0 | 0 | 0 | 0 |
ALLR Frequently Asked Questions
What is Allarity Therapeutics, Inc. stock symbol ?
Allarity Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol ALLR
What is Allarity Therapeutics, Inc. stock quote today ?
Allarity Therapeutics, Inc. stock price is $0.3011 today.
Is Allarity Therapeutics, Inc. stock public?
Yes, Allarity Therapeutics, Inc. is a publicly traded company.